Screener
Castle Biosciences CSTL Q2 2026 earnings
Reported July 30, 2026 · After market close
Revenue$103.5MBeat by $17.3M
EPS-$0.07Beat by $0.34
Revenue estimate$86.2M
EPS estimate-$0.41
“We believe our strong growth through the first half of 2026 demonstrates the clinical value our tests bring to patient care and the dedication of our talented team to deliver results so that our clinician customers and patients can act with confidence.”
Next report
Nov 2, 2026 (in a month)Revenue estimate$92.1M
EPS estimate-$0.38
Valuation & ratios
Valuation
as of 09/17/26Versus estimates
Revenue
Diluted EPS
FAQ
- When did Castle Biosciences report Q2 2026 earnings?
- Castle Biosciences (CSTL) reported Q2 2026 earnings on July 30, 2026 after market close.
- What were Castle Biosciences's Q2 2026 revenue and EPS?
- Castle Biosciences reported revenue of $103.5M and eps of $-0.07 for Q2 2026.
- Did Castle Biosciences beat estimates in Q2 2026?
- Revenue beat the consensus estimate of $86.2M by $17.3M. EPS beat the consensus estimate of $-0.41 by $0.34.
- How did Castle Biosciences's Q2 2026 results compare year-over-year?
- Compared to the same quarter a year prior, revenue grew 20.1% from $86.2M a year earlier.
- Where can I find Castle Biosciences's Q2 2026 SEC filings?
- You can read the 8-K earnings release (0001628280-26-051045) and the 10-Q periodic report (0001628280-26-051052) directly on SEC EDGAR. The filing index links above go to sec.gov.
